Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma.

Future OncologyVol. 19, No. 17 EditorialFutibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinomaRita Khoury, Claude Chahine, Rebecca Ibrahim, Nadine Khalife, Mohammad Saleh & Khalil SalehRita KhouryInternational Department, Gustave Roussy Cancer Campus, Villejuif, 94800, FranceSearch for more papers by this author, Claude ChahineInternational Department, Gustave Roussy Cancer Campus, Villejuif, 94800, FranceSearch for more papers by this author, Rebecca IbrahimInternational Department, Gustave Roussy Cancer Campus, Villejuif, 94800, FranceSearch for more papers by this author, Nadine KhalifeDepartment of Head & Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, FranceSearch for more papers by this author, Mohammad SalehDepartment of Hematology & Oncology, Lebanese American University Medical Center–Rizk Hopsital, Beirut, 11-3288, LebanonSearch for more papers by this author & Khalil Saleh *Author for correspondence: Tel.: +33 142 114 211; E-mail Address: khalil_saleh@live.comhttps://orcid.org/0000-0002-2985-2202International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, FranceSearch for more papers by this authorPublished Online:9 Jun 2023https://doi.org/10.2217/fon-2023-0318AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: futibatinibinfigratinibintrahepatic cholangiocarcinomapemigatinibReferences1. Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist 21(5), 594–599 (2016).Crossref, Medline, Google Scholar2. Florio AA, Ferlay J, Znaor A et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer 126(11), 2666–2678 (2020).Crossref, Medline, Google Scholar3. Jusakul A, Cutcutache I, Yong CH et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 7(10), 1116–1135 (2017).Crossref, Medline, CAS, Google Scholar4. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).Crossref, Medline, Google Scholar5. Banales JM, Marin JJG, Lamarca A et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 17(9), 557–588 (2020).Crossref, Medline, Google Scholar6. Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control 24(3), 1073274817729245 (2017).Crossref, Google Scholar7. Oh D-Y, Ruth He A, Qin S et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 1(8), EVIDoa2200015 (2022).Crossref, Google Scholar8. Lamarca A, Palmer DH, Wasan HS et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 22(5), 690–701 (2021).Crossref, Medline, CAS, Google Scholar9. Arai Y, Totoki Y, Hosoda F et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59(4), 1427–1434 (2014).Crossref, Medline, CAS, Google Scholar10. Farshidfar F, Zheng S, Gingras M-C et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 18(11), 2780–2794 (2017).Crossref, Medline, CAS, Google Scholar11. Krook MA, Reeser JW, Ernst G et al. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br. J. Cancer 124(5), 880–892 (2021).Crossref, Medline, CAS, Google Scholar12. Abou-Alfa GK, Sahai V, Hollebecque A et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21(5), 671–684 (2020).Crossref, Medline, CAS, Google Scholar13. Javle M, Lowery M, Shroff RT et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J. Clin. Oncol. 36(3), 276–282 (2018).Crossref, Medline, CAS, Google Scholar14. Abou-Alfa GK, Borbath I, Goyal L et al. PROOF 301: a multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement. JCO 40(Suppl. 16), TPS4171–TPS4171 (2022).Crossref, Google Scholar15. Mauro E, Ferrer-Fàbrega J, Sauri T et al. New challenges in the management of cholangiocarcinoma: the role of liver transplantation, locoregional therapies, and systemic therapy. Cancers (Basel) 15(4), 1244 (2023).Crossref, Medline, CAS, Google Scholar16. Sootome H, Fujita H, Ito K et al. Futibatinib is a novel irreversible FGFR 1–4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 80(22), 4986–4997 (2020).Crossref, Medline, CAS, Google Scholar17. Bahleda R, Meric-Bernstam F, Goyal L et al. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors. Ann. Oncol. 31(10), 1405–1412 (2020).Crossref, Medline, CAS, Google Scholar18. Doi T, Shitara K, Kojima T et al. Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors. Cancer Sci. 114(2), 574–585 (2023).Crossref, Medline, CAS, Google Scholar19. Goyal L, Meric-Bernstam F, Hollebecque A et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N. Engl. J. Med. 388(3), 228–239 (2023).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 19, No. 17 STAY CONNECTED Metrics Downloaded 7 times History Received 13 April 2023 Accepted 24 May 2023 Published online 9 June 2023 Published in print June 2023 Information© 2023 Future Medicine LtdKeywordsfutibatinibinfigratinibintrahepatic cholangiocarcinomapemigatinibFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download